The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX expands its clinical-stage pipeline through its proprietary...
HONG KONG, June 26, 2026 /PRNewswire/ -- Hong Kong Exchanges and Clearing Limited (HKEX) today (Friday) welcomed the listing of the first exchange traded...
HONG KONG, June 26, 2026 /PRNewswire/ -- Hong Kong Exchanges and Clearing Limited (HKEX) today (Friday) welcomed the listing of the first exchange traded...
~ Crunchyroll Simulcast Confirmed! "Kagurabachi" Anime World Tour Part 1 Confirms Premiere Screening at Otakon! ~ TOKYO, June 26, 2026 /PRNewswire/ -- Anime...
BEIJING, June 26, 2026 /PRNewswire/ -- The Fourth China International Supply Chain Expo (CISCE) has opened its Healthy Life Chain section, drawing more than...